Exhaled-breath glucose monitoring

Exhaled-breath glucose monitoring aims to track diabetes-relevant metabolic state from a breath sample instead of a fingerstick blood test or implanted continuous glucose monitor. The commercially furthest-along devices in this category actually detect breath acetone or ketones — metabolic byproducts correlated with fat metabolism and, in diabetes management, with risk of diabetic ketoacidosis — rather than glucose molecules themselves; PranaQ, Invoy Technologies and LEVL all build breath acetone/ketone sensing devices marketed into metabolic-health and diabetes-adjacent use cases. Invoy Technologies holds patents covering its breath analysis device and wearable breath-analyte measurement hardware, and runs an active ketone research device program for breath acetone studies. LEVL’s breath ketone analyzer targets fat-metabolism tracking. A newer entrant, PREEVNT, is pursuing a more direct blood-glucose claim with its ISAAC device, which debuted as a non-invasive blood glucose alert device at the CES Digital Health exhibit and is publicly documenting its path through FDA review.

The key directions of exhaled-breath glucose monitoring are:

1. Breath acetone/ketone sensing (Breath Acetone Ketone Sensing): electrochemical or semiconductor gas sensors detecting breath acetone as a proxy for fat metabolism and diabetes-relevant ketosis — PranaQ, Invoy Technologies, LEVL.
2. Direct breath glucose alert devices (Breath Glucose Alert Devices): devices claiming to alert on blood-glucose status directly from a breath sample rather than via a ketone proxy — PREEVNT’s ISAAC.
3. Wearable breath analyte measurement (Wearable Breath Analyte Measurement): patented wearable form factors for continuous or repeated breath-analyte sampling outside a single handheld reading — Invoy Technologies.
4. FDA clearance pathway navigation (FDA Clearance Pathway): the regulatory-validation journey each device must complete before its glucose or ketone claim can be marketed as a medical diagnostic — publicly documented by PREEVNT for ISAAC.

Sectoral value chain#

[breath sample collection] ──> [gas sensor detection (acetone/VOC)] ──> [signal processing & blood-reference calibration]
                                                    │
                                       (alert/reading generation)
                                                    │
                                                    ▼
[diabetes management integration] <─── [regulatory clearance (FDA)] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Electrochemical/semiconductor gas sensing (Breath Acetone Ketone Sensing): solid-state gas sensors tuned to detect breath acetone at parts-per-billion concentrations, the core chemistry behind PranaQ, Invoy Technologies and LEVL’s devices.
• Direct glucose-correlate detection (Breath Glucose Alert Devices): sensor approaches aiming to correlate breath signal more directly with blood glucose rather than the acetone/ketone intermediate, PREEVNT’s stated technical direction for ISAAC.
• Wearable continuous breath sampling (Wearable Breath Analyte Measurement): patented wearable hardware (Invoy Technologies) extends breath analysis from a single spot-check reading toward more continuous monitoring.

The stack applies solid-state gas-sensing chemistry to breath acetone and related volatile organic compounds, with the field’s leading edge now pushing toward a more direct blood-glucose correlate rather than the established ketone proxy.

1. Breath acetone/ketone gas sensing (Breath Acetone Ketone Sensing):
   • PranaQ, Invoy Technologies and LEVL all use electrochemical or semiconductor sensors tuned to detect breath acetone, a metabolic byproduct of fat oxidation that rises during ketosis and carries diabetes-relevant risk information for ketoacidosis monitoring.
2. Wearable breath-analyte hardware (Wearable Breath Analyte Measurement):
   • Invoy Technologies’ patented wearable measurement device extends breath analysis beyond a single handheld reading toward more frequent or continuous sampling.
3. Direct blood-glucose breath correlate (Breath Glucose Alert Devices):
   • PREEVNT’s ISAAC device pursues a technical approach aimed at a more direct blood-glucose alert claim, distinguishing it from the acetone/ketone-proxy devices that currently anchor the category’s commercial base.
4. Regulatory validation pathway (FDA Clearance Pathway):
   • PREEVNT has publicly documented ISAAC’s path through FDA review, illustrating the clinical-validation bar every device in this category must clear before its specific glucose or ketone claim can be marketed as a diagnostic rather than a wellness product.